- Home
- Reports Store
- Medical Devices
In Vitro Diagnostics (IVD) Market
Customise your request
Need this report to answer something it does not cover? Tell us the decision you are facing and we will scope the work — or point you to a study that already answers it.
info@cortexmeridian.com+971 56 483 5090Report Scope
| Report ID / SKU | CM-MD-0001 |
|---|---|
| Report Code | CM-MD-P1-1001 |
| Report Type | Market Analysis & Forecast |
| Base Year | 2025 |
| Historical Period | 2021–2025 |
| Forecast Period | 2026–2035 |
| Geographic Scope | Global |
| Global Coverage | Yes |
| Regions Covered | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Countries Covered | US; Canada; Mexico; UK; Germany; France; Italy; Spain; Netherlands; Switzerland; China; India; Japan; South Korea; Australia; Brazil; Argentina; Saudi Arabia; UAE; South Africa (20 countries) |
| Market Size Unit | USD Billion |
| Volume Unit | Instruments / Tests / Reagent Units |
| Report Format | PPT / WORD / EXCEL / PDF |
| Page Count | 180-220 |
| Delivery Timeline | 48 hours |
| Sample Available | Yes |
| Author / Analyst | Cortex Meridian Medical Devices Analyst Team |
| Publish Date | October 2026 |
| Last Updated | 2026-10-06 |
Market Overview & Definition

The global In Vitro Diagnostics (IVD) market is valued by Cortex Meridian Research at approximately USD 107.4 billion in 2025 and is projected to reach about USD 181.7 billion by 2035, implying a CAGR of 5.4% during 2025–2035. The market is no longer expanding primarily through analyzer placements; value creation is increasingly concentrated in recurring reagents, specialty assays, software, digital pathology and integrated laboratory workflows. This matters because the installed base of analyzers in mature markets is already extensive, so vendors that can increase test menu breadth, automation throughput and clinical utility per installed instrument are better positioned to grow revenue without relying on wholesale replacement cycles.
The most important structural shift is the movement from conventional core-laboratory testing toward higher-value molecular, oncology, pathology and near-patient workflows. Screening programs, chronic-disease monitoring and companion diagnostics are increasing the frequency and complexity of testing, while laboratories are under pressure to process greater volumes with fewer skilled technicians. That is accelerating automation and consolidation around larger platform ecosystems. At the same time, reimbursement controls, China’s healthcare pricing reforms and normalized post-pandemic infectious-disease demand prevent the market from returning to the unusually high growth rates seen during COVID-19.
Competitive strategy is becoming increasingly ecosystem-led. Roche’s diagnostics portfolio expansion and proposed PathAI acquisition strengthen its ability to connect tissue diagnostics, digital pathology and oncology biomarkers. Danaher’s planned Masimo acquisition points to a different form of convergence, combining diagnostics with connected monitoring and sensor data. Abbott, Siemens Healthineers, bioMérieux, Sysmex and Thermo Fisher are also deepening specialization in high-throughput, molecular and disease-specific testing. The result is a market where share gains are likely to come from workflow ownership, recurring assay pull-through and data integration rather than from stand-alone hardware innovation alone.
Report Description
The In Vitro Diagnostics (IVD) Market covers revenue generated from the defined medical-device products, related consumables and software/services where directly attached to the device workflow. The report excludes unrelated pharmaceuticals and stand-alone healthcare services. The scope is designed for manufacturers, suppliers, distributors, hospitals, diagnostic providers, investors and strategy teams evaluating demand, technology shifts, pricing and competitive opportunity.
Overall Market Dynamics
Drivers
Rising chronic and infectious disease burden, preventive screening, decentralized testing, molecular adoption, automation and recurring reagent demand.
Restraints / Risks
Reimbursement pressure, laboratory budget constraints, regulatory complexity, commoditization in mature assays and post-pandemic normalization.
Opportunities
Multiplex testing, high-sensitivity assays, decentralized molecular testing, lab automation, companion diagnostics, APAC expansion.
Strategic themes
AI/connectivity, workflow efficiency, reimbursement, regulatory approvals, recurring consumables/service revenue, and regional access expansion.
Segmentation & Scope

By product: instruments, reagents, services; by technology: molecular diagnostics, immunoassay, clinical chemistry, hematology, coagulation, microbiology; by application; by test location: central lab, point-of-care, home/self testing; by end user: hospitals, laboratories, home care; by geography.
Regional & Country Outlook

COUNTRY CHAPTER COVERAGE 1. US: market size & forecast; installed lab base; FDA-cleared assays; reimbursement; core-lab vs POC mix; Roche/Abbott/Danaher/Siemens positioning; molecular and pathology adoption. 2. Canada: market size & forecast; provincial lab procurement; centralized testing; public reimbursement; molecular/POC adoption; supplier landscape. 3. UK: NHS diagnostics demand; pathology-network consolidation; procurement; molecular and digital pathology adoption; reimbursement and laboratory modernization. 4. Germany: hospital/lab demand; reimbursement; automation; molecular diagnostics; pathology digitization; leading supplier penetration. 5. France: public/private lab structure; reimbursement; screening programs; molecular testing; procurement and competitive landscape. 6. Italy: regional laboratory networks; procurement; screening; POC adoption; supplier/channel structure. 7. Spain: public hospital/lab demand; decentralized testing; molecular diagnostics; reimbursement; distributor landscape. 8. Netherlands: high automation; digital pathology; precision diagnostics; centralized labs; innovative assay adoption. 9. Switzerland: premium diagnostics adoption; pharma-linked companion diagnostics; pathology and molecular testing; supplier ecosystem. 10. China: market size & forecast; localization; volume-based procurement; hospital lab expansion; domestic vs multinational suppliers; molecular testing. 11. India: private diagnostics chains; hospital labs; POC demand; price tiers; local manufacturing; infectious-disease and chronic-disease testing. 12. Japan: high-value diagnostics; aging-related screening; reimbursement; automation; molecular testing; domestic supplier competition. 13. South Korea: advanced hospital labs; molecular diagnostics; oncology testing; digital pathology; reimbursement; local innovation. 14. Australia: public/private pathology networks; reimbursement; POC adoption; molecular testing; remote-care diagnostics. 15. Brazil: private lab chains; public health testing; infectious disease; distributor economics; reimbursement/access. 16. Argentina: public/private laboratory demand; currency/pricing effects; imported devices; infectious disease and screening. 17. Saudi Arabia: Vision 2030 diagnostics expansion; hospital/lab capacity; localization; tenders; molecular and POC adoption. 18. UAE: private hospital/lab investment; premium diagnostics; centralized labs; molecular testing; distributor landscape. 19. South Africa: public/private lab split; infectious disease testing; POC access; procurement; local distribution.
Competitive Landscape & Companies Covered
Abbott; Roche Diagnostics; Danaher; Siemens Healthineers; Thermo Fisher Scientific; BD; bioMérieux; QIAGEN; QuidelOrtho; Bio-Rad Laboratories; Sysmex; Illumina
Pricing & Ecosystem
Pricing, Cost & Revenue Intelligence
Pricing intelligence benchmarks capital-system ASPs, disposable/consumable pricing, procedure-linked device pricing, service contracts, software subscriptions and regional tender dynamics where applicable. The model distinguishes capital equipment from recurring revenue and evaluates discounting, bundling, distributor margins, reimbursement sensitivity and premium technology price realization.
Value Chain & Ecosystem Analysis
The ecosystem maps component and sensor suppliers, materials vendors, device OEMs, software/AI partners, contract manufacturers, sterilization and packaging providers, distributors, hospitals/diagnostic laboratories/ASCs, clinicians, payers and regulators. The analysis identifies control points in the value chain, recurring-revenue pools, channel dependencies and partnership opportunities.
Opportunity & White-Space Analysis
A weighted opportunity model scores product segments, technologies, countries, end users and accounts using growth, market size, clinical adoption, reimbursement, competitive intensity, regulatory accessibility and margin potential. Priority white spaces include Multiplex testing, high-sensitivity assays, decentralized molecular testing, lab automation, companion diagnostics, APAC expansion.
Executive Summary
The IVD market is entering a more mature but strategically stronger phase. Cortex Meridian Research estimates the market at USD 107.4 billion in 2025, rising to approximately USD 181.7 billion by 2035 at a CAGR of 5.4%. Growth is supported less by greenfield instrument placements and more by higher-value recurring revenue from reagents, specialty assays, molecular testing, digital pathology and laboratory automation.
The strategic implication is that vendors with broad installed bases and expandable test menus have a structural advantage. Roche’s move toward AI-enabled pathology through PathAI, together with continued expansion in oncology and molecular diagnostics, illustrates how major suppliers are trying to capture more of the diagnostic workflow. Danaher’s planned Masimo acquisition suggests further convergence between diagnostic testing and connected physiological data. These moves can increase revenue per account and improve customer stickiness, but pricing pressure, reimbursement scrutiny and localization policies—especially in China—will continue to constrain growth in commoditized assay categories. The market therefore favors differentiated, high-clinical-value testing over volume-led expansion.
Key Takeaways
- 2025 Cortex normalized estimate: USD 107.4 billion
- 2035 normalized outlook: USD 181.7 billion
- Normalized 2025–2035 CAGR: 5.4%
- Key growth drivers: Rising chronic and infectious disease burden, preventive screening, decentralized testing, molecular adoption, automation and recurring reagent demand.
- Priority opportunity areas: Multiplex testing, high-sensitivity assays, decentralized molecular testing, lab automation, companion diagnostics, APAC expansion.
- Primary competitive set: Abbott; Roche Diagnostics; Danaher; Siemens Healthineers; Thermo Fisher Scientific; BD; bioMérieux; QIAGEN; QuidelOrtho; Bio-Rad Laboratories; Sysmex; Illumina
Table of Contents
List of Tables
- Global market value, 2021–2035
- Market by product/device type
- Market by technology
- Market by application/procedure
- Market by end user
- Market by region
- Country market sizing
- Installed base/procedure/test indicators
- ASP/pricing benchmark
- Company/product benchmark
- Opportunity attractiveness scoring
List of Figures
- Market size and CAGR outlook
- Segment attractiveness matrix
- Technology adoption curve
- Regional opportunity heat map
- Competitive positioning matrix
- Value-chain ecosystem map
- Pricing/revenue model
- Opportunity prioritization matrix
Research Methodology
Methodology
Cortex Meridian Research applies a triangulated market-sizing framework combining company disclosures, regulatory databases, procedure/test volumes, installed-base indicators, shipment and utilization data, hospital and laboratory purchasing patterns, reimbursement signals, product approvals, and primary research. Public market benchmarks are used only as external calibration points; Cortex values are normalized to the defined scope and forecast period. Forecasts consider technology adoption, procedure/test growth, replacement cycles, pricing, reimbursement, regulatory changes, and regional healthcare investment.
Data Sources & Validation
Company annual reports and investor materials; FDA, EMA and other regulatory databases; WHO and national health agencies; peer-reviewed clinical literature; procurement and reimbursement sources; hospital/laboratory statistics; trade and shipment indicators; company product portfolios; primary interviews; and public market benchmarks used for calibration.
FAQ — Buyer Questions
Q: What is the 2025 global In Vitro Diagnostics (IVD) market size? A: Cortex Meridian Research estimates it at approximately USD 107.4 billion.
Q: What is the 2035 market outlook? A: The normalized outlook is approximately USD 181.7 billion, based on a 5.4% CAGR assumption.
Q: What are the major growth drivers? A: Rising chronic and infectious disease burden, preventive screening, decentralized testing, molecular adoption, automation and recurring reagent demand.
Q: Which opportunities should suppliers prioritize? A: Multiplex testing, high-sensitivity assays, decentralized molecular testing, lab automation, companion diagnostics, APAC expansion.
Customization Options
Customization can include country-level sizing, procedure/test volumes, installed base, ASP benchmarking, hospital/lab account mapping, competitor benchmarking, product pipeline analysis, regulatory and reimbursement tracking, KOL mapping, distributor/channel assessment, and opportunity prioritization.
Need something this report does not cover?
Describe the decision you are facing. If a published study already answers it we will point you there; if not, we will scope the work and come back with timeline and cost.
CM-MD-0001 · CM-MD-P1-1001 · 180-220 pages · Published October 2026 · Cortex Meridian Medical Devices Analyst Team
